ClinicalTrials.gov
ClinicalTrials.gov Menu

Implications of Amyloid Pathology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00900770
Recruitment Status : Unknown
Verified December 2009 by National Institute on Aging (NIA).
Recruitment status was:  Recruiting
First Posted : May 13, 2009
Last Update Posted : December 29, 2009
Sponsor:
Information provided by:
National Institute on Aging (NIA)

May 11, 2009
May 13, 2009
December 29, 2009
November 2008
March 2014   (Final data collection date for primary outcome measure)
Pittsburgh Compound B (PiB) and F-18 fluorodeoxyglucose (FDG) PET Scan [ Time Frame: at 1 month ]
Same as current
Complete list of historical versions of study NCT00900770 on ClinicalTrials.gov Archive Site
  • Cognitive and functional assessments [ Time Frame: Baseline and annually for 5 years ]
  • Lumbar Puncture (optional) [ Time Frame: Baseline ]
Same as current
Not Provided
Not Provided
 
Implications of Amyloid Pathology
Implications of Amyloid Deposition in Clinically Normal Older Individuals
The purpose of this study is to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical Alzheimer's Disease (AD).

There is compelling evidence supporting amyloid as one of the key pathologic agents in AD. Autopsy studies suggest the amount and location of fibrillar amyloid deposition does not relate strongly to the degree and type of clinical impairment, compared to tau pathology and neuronal loss. A substantial percentage of individuals known to be cognitively intact prior to death demonstrate significant amyloid pathology at autopsy. PIB-PET studies of older normal individuals have also demonstrated significant amyloid deposition in substantial percentages.

This study will test the hypothesis that amyloid is associated with synaptic dysfunction and neuronal damage. While some individuals are able to compensate for amyloid-related toxicity for an extended time period, sensitive imaging and neuropsychological markers will reveal that normal subjects with evidence of high amyloid burden do demonstrate evidence of abnormality consistent with prodromal AD.

The study will use a combination of functional, structural, and cognitive measures to detect early effects of amyloid deposition, and will utilize PIB retention in order to characterize the relationship of amyloid to neuropsychological and imaging markers of prodromal AD. The relationship of PIB retention to genetic, plasma and cerebrospinal fluid (CSF) biomarkers will be explored. These preliminary data will be used to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical AD. When completed, this project will either provide evidence that the presence of amyloid deposition is a useful biomarker for incipient AD or raise the possibility that amyloid deposition examined in isolation is insufficient to predict early symptoms and progression of AD.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Longitudinal cohort of the Massachusetts Alzheimer's Disease Research Center and community volunteers
Alzheimer's Disease
Not Provided
  • PIB+ NC
    PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
  • PIB- NC
    PIB negative, cognitively normal individuals without amyloid deposition

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
Same as current
March 2014
March 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age range from 60 to 90 years
  • Clinical Dementia Rating (CDR) Score of 0
  • Mini Mental State Exam of 27-30
  • A study partner who can answer questions pertaining to daily functioning
  • Perform within 1.5 standard deviation of age and education matched norms on screening tests of attention and executive function, language, visuospatial perception and episodic memory
  • Stable medications for at least 30 days
  • Fluent in English
  • Modified Hachinski Score of <4
  • Geriatric Depression Scale Score <10

Exclusion Criteria:

  • Diagnosis of MCI or dementia
  • Individuals with contraindications to MRI (i.e., implanted metal including pacemakers, cerebral spinal fluid shunts, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in the eyes and those with a history of claustrophobia)
  • Unstable medications or on medications with CNS effects including cholinesterase inhibitors, memantine, and antidepressants
  • Major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder, or treatment with ECT (mild depression that is well treated with stable dose of SSRI antidepressants will be allowed)
  • Multiple sclerosis or other autoimmune disorders
  • Huntington's disease
  • Head injury, post-traumatic dementia or seizures
  • Metabolic encephalopathy, CNS infection, hydrocephalus
  • Cardiovascular disease, stroke, congestive heart failure
  • Substance abuse within the past 2 years
  • Active cancer
  • Active hematological, renal, pulmonary, endocrine or hepatic disorders
Sexes Eligible for Study: All
60 Years to 90 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00900770
IA0158
2P50AG005134-268381
2P50AG005134 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Reisa Sperling, MD, Director of Clinical Research, Memory Disorders Unit, Brigham and Women's Hospital
National Institute on Aging (NIA)
Not Provided
Principal Investigator: Reisa Sperling, MD Director of Clinical Research, Memory Disorders Unit, Brigham and Women's Hospital
National Institute on Aging (NIA)
December 2009